Alvotech(ALVOW)
LUXEMBOURG, LuxembourgBiotechnology
Focus: Alvotech is a Luxembourg-based public biotech specializing in biosimilars across immunology, neurology, gastroenterology, and ophthalmology. The company has two FDA-approved biosimilars on the market and a robust Phase 3 pipeline targeting high-value biologic references.
Profile data last refreshed 1h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
9-8 this month
Cooling — net -8 jobs in 30d
14 added, 22 removed. Slower than typical.
Should You Work at Alvotech?
AI assessmentStrong portfolio fit for regulatory, manufacturing, and supply-chain professionals targeting established biosimilar companies; limited upside for R&D-focused talent given narrow hiring and Phase 1 oncology bet.
Why Work Here
- Two commercial-stage biosimilars (SELARSDI, SIMLANDI) generating revenue in fast-growing immunology indications
- Deep Phase 3 pipeline with 10 programs targeting blockbuster references (adalimumab, golimumab, vedolizumab, aflibercept) across high-prevalence diseases
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
14 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Growth
FDA-approved ustekinumab biosimilar targeting IL-12/IL-23 pathway; first-to-market advantage in immunology segment.
Help build intelligence for Alvotech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.